Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.
| Revenue (Most Recent Fiscal Year) | $400.02M |
| Net Income (Most Recent Fiscal Year) | $-35.51M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.16 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4.77% |
| Net Margin (Trailing 12 Months) | -8.88% |
| Return on Equity (Trailing 12 Months) | -9.20% |
| Return on Assets (Trailing 12 Months) | -3.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.03 |
| Inventory Turnover (Trailing 12 Months) | 0.83 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.54 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.60 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.71 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.70 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.53M |
| Free Float | 45.27M |
| Market Capitalization | $1.66B |
| Average Volume (Last 20 Days) | 0.37M |
| Beta (Past 60 Months) | 0.78 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 84.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |